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Summary In 1980 the World Health Organization declared that smallpox was eradicated from
the world, and routine smallpox vaccination was discontinued. Nevertheless, samples of the
smallpox virus (variola virus) were retained for research purposes, not least because of fears that
terrorist groups or rogue states might also have kept samples in order to develop a bioweapon.
Variola virus represents an effective bioweapon because it is associated with high morbidity and
mortality and is highly contagious. Since September 11, 2001, countries around the world have
begun to develop policies and preparedness programs to deal with a bioterror attack, including
stockpiling of smallpox vaccine. Smallpox vaccine itself may be associated with a number of
serious adverse events, which can often be managed with vaccinia immune globulin (VIG). VIG
may also be needed as prophylaxis in patients for whom pre-exposure smallpox vaccine is
contraindicated (such as those with eczema or pregnant women), although it is currently not
licensed in these cases. Two intravenous formulations of VIG (VIGIV Cangene and VIGIV Dynport)
have been licensed by the FDA for the management of patients with progressive vaccinia, eczema
vaccinatum, severe generalized vaccinia, and extensive body surface involvement or periocular
implantation following inadvertent inoculation.
# 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights
reserved.Introduction
Following an intensive smallpox vaccination strategy
initiated in 1967, smallpox was finally declared eradicated
from the world by the World Health Organization (WHO) in
1980.1,2 Routine smallpox vaccination of the general public
was discontinued in the USA in 1972.3,4 British and American
armed forces continued smallpox vaccination for a number of* Tel.: +41 21 692 4112; fax: +41 21 692 4125.
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doi:10.1016/j.ijid.2005.12.001years, but routine vaccination was eventually discontinued in
the early 1980s in the UK,5 and in 1990 in the USA.6
Prior to September 11, 2001, awareness of a potential
biothreat existed but countermeasures were not considered
an urgent matter. Following September 11, 2001, however,
the bioterrorism threat was brought sharply into focus,
particularly with the anthrax attacks via the US mail. A
bioterrorist agent of particular concern is the smallpox virus
(variola virus) which, for a variety of reasons (discussed
below), constitutes an ideal terrorist weapon of mass
destruction.7,8 There remains a low but very real risk of
variola virus release, whether intentional or accidental.9Published by Elsevier Ltd. All rights reserved.
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variola virus were retained for research purposes (for exam-
ple, to develop more effective vaccines), not least because of
fears that terrorist groups or states might possess clandestine
samples of the virus.10 There are two official repositories of
variola virus, located in the WHO collaborating centers in the
USA (Centers for Disease Control and Prevention (CDC),
Atlanta, GA) and Russia (State Research Centre of Virology
and Biotechnology ‘‘VECTOR’’, Koltsovo, Novosibirsk region),
but there is a belief amongst experts that other states or
groups may also possess virus samples with the aim of pursuing
biological weapons programs.3 It has also been reported that
the former Soviet Union stockpiled 20 tons of variola virus
during the 1970s, and subsequently developed a plant capable
of producing up to 100 tons of virus per year.3,11 Of even
greater concern are reports that Russian scientists bioengi-
neered variola virus during the Cold War in order to make it
even more dangerous, such as by increasing its pathogenicity
by inserting genes for foreign toxins, or creating novel strains
of the virus capable of degrading the human immune
response.12 US officials have also indicated their belief that
other states may possess undisclosed stocks of variola virus.10
Smallpoxrepresentsaneffectivebioweaponforanumberof
reasons. First, smallpox is associated with very high morbidity
and high overall mortality rates (approximately 30%).9,13 His-
torically, smallpox has been reported as presenting in three
different forms (ordinary, flat, and hemorrhagic), probably
depending on host rather than viral factors.4 The flat and
hemorrhagicmanifestations of the disease were nearly always
fatal.4 Patients who recover from smallpox may be left with
serious sequelae, including extensive scarring of the skin,13
hearing loss or blindness14 or, more rarely, other organ
damage.13 Second, smallpox is a highly contagious disease that
is spread easily fromperson to person, and infection invariably
results in symptomatic disease.7 Furthermore, it has been
shown that aerosolized variola virus is capable of spreading
overconsiderabledistances,andthat infectionmayresulteven
at lowviraldoses.7 Inaddition,unlikeanthrax,smallpoxcarries
a risk of secondary and further generations of infection.15
Finally, smallpox vaccine is generally effective in preventing
illness if it isgivenwithin72 hoursofexposure,andmayprevent
death if given within five days.15 Unfortunately, people
exposed to variola virus are usually asymptomatic for up to
17 days, given the 9—17-day incubation period of the disease,3
by which time vaccination is almost certainly too late.
In a simulated smallpox attack on the USA (entitled ‘Dark
Winter’), it was calculated that 30 g of weaponized variola
virus could infect 3000 individuals.3 In a scenario inwhich 3000
persons were initially infected in attacks on three different US
states, it was determined that 16 000 people would be
infected in 25 states by day 22 following the attack, and that
the viruswould have spread to other countries by international
travelers from the USA. Assuming worst-case conditions (i.e.,
in the absence of an effective vaccination and isolation strat-
egy), it was calculated that as many as 3 million cases of
smallpox may ultimately result, leading to 1 million deaths.3
Since vaccination would be the only viable protection
against disease spread following a terrorist attack with var-
iola virus, restoration of the US National Smallpox Vaccina-
tion Program was announced in December 2002, and
President George W. Bush was among the first to be vacci-
nated.16 In the UK, the Ministry of Defence announced that itwould offer vaccination against smallpox to a small number
of specialist military personnel, whose specialization means
they face a greater risk of exposure to smallpox.17
Reinstatement of smallpox vaccination to the military and
other individuals brings with it a number of responsibilities,
including: Development of policies and strategic planning in the
event of a bioterrorist attack. Stockpiling of vaccine supplies.
 The need tomanage serious adverse events associatedwith
the smallpox vaccine (including encephalitis, eczema vac-
cinatum, generalized vaccinia and myopericarditis), parti-
cularly in view of the increased prevalence of immune
suppression from congenital or acquired illness, organ or
bone marrow transplantation, cancer, eczema and other
dermatological conditions, etc. compared to the 1960s.9 The need for stockpiling of vaccinia immune globulin (VIG)
supplies for management of serious adverse reactions to
the vaccine, particularly as no international stockpile of
VIG was maintained following certification of smallpox
eradication.2 Given the changing characteristics of the
general population described above, the need for VIG is
likely to be increased compared to the 1960s, and com-
pared to controlled studies conducted by the Department
of Defense (DoD),18 for the management of, and possibly
prophylaxis against, vaccine-related serious adverse
events. It has also been suggested that VIG might even
be life-saving in unvaccinated persons who have come into
contact with people exposed to variola virus itself, and
may help to limit the spread of disease,19 although neither
this nor prophylaxis against vaccine-related events are
currently licensed indications for VIG.
Response and preparedness programs
The Global Outbreak Alert and Response Network (GOARN)
was developed by the WHO’s Department of Communicable
Diseases, Surveillance and Response in 1997 in order to
enhance the world’s collaboration in containment of infec-
tious diseases, but does not replace the need for increased
national public health investment in preparedness for inten-
tional outbreaks of diseases such as smallpox.2 Since Sep-
tember 11, 2001, many countries have initiated their own
preparedness programs.
In the USA, for example, the CDC initiated a Bioterrorism
Preparedness and Response Program to assess and progress a
combination of countermeasure strategies. This program
includes a wide range of plans and policies, such as funding
assigned specifically to deal with bioemergencies; local and
regional response plans, communication and training; and
disease detection, reporting, patient isolation and manage-
ment. Specifically, in 2003, the CDC’s Advisory Committee on
Immunization Practices (ACIP) pre-event vaccination pro-
gram made a series of recommendations:20 (1) Smallpox
vaccination should be carried out for persons designated
by public health authorities to conduct investigation and
follow-up of initial smallpox cases that might necessitate
direct patient contact. (2) Each state and territory should
establish and maintain at least one smallpox response team.
(3) Pre-exposure vaccination is contraindicated for persons
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exfoliative skin conditions, conditions associated with immu-
nosuppression, infants under 1 year of age, those with a
serious allergy to any component of the vaccine, and preg-
nant or breastfeeding women.20 More recently, myopericar-
ditis has been added to the list of anticipated adverse
reactions to smallpox vaccination,21 and symptomatic or
asymptomatic heart disease should now be considered a
contraindication to pre-event vaccination.22,23
Smallpox vaccine stockpiles in the USA include two gen-
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rinted with permission from The American College of Emergency Physicfactured using modern, serum- and protein-free cell
culture techniques (Acambis plc), the aim being to
improve the safety profile compared to first generation
vaccines while providing the same protection against
infection.24 ACAM2000 is currently available in the USA
as an Investigational New Drug, although Acambis was
due to file a Biologics License Application before the end
of 2005.With regard to adverse reactions to smallpox vaccines,
the CDC has advised that vaccinated persons who develop
progressive vaccinia, eczema vaccinatum, severe general-
ized vaccinia or those with inadvertent inoculation else-
where from the vaccination site might benefit from therapy
with VIG or cidofovir.20 It should be noted that cidofovir has
never been used to treat vaccinia virus infections in
humans,22 has not been approved by the FDA for this
indication,20 and is associated with a number of serious
adverse effects, including potentially irreversible renal
toxicity.25 It is therefore reserved as second-line therapy
after VIG in this setting.25 VIG may also be needed as
prophylaxis — for example, in persons for whom smallpoxtheir clinical presentation (from Thorne et al.)9
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Table 2 Incidence of serious adverse reactions to smallpox
vaccine in worldwide reports from 1924 through the 1960s
(data from Poland et al.)6
Adverse reaction Incidence (per million
vaccinations)
Encephalitis 2—1200
Encephalopathy 3—50
Eczema vaccinatum 8—80
Progressive vaccinia 1
Generalized vaccinia 1—70vaccine is contraindicated (such as those with eczema or
pregnant women),26 although it is currently not licensed in
these cases.25
As of January 31, 2003, enough VIG was available in the
USA to treat the anticipated number of serious adverse
reactions that would result from vaccination, based on a
ratio of 1:10 000.20,27 Two intravenous (IV) formulations of
VIG have been licensed by the FDA for the management of a
range of adverse reactions to smallpox vaccination (VIGIV
Cangene and VIGIV Dynport), described in more detail
below.28,29 In August 2002, Cangene was awarded a contract
by the CDC to provide up to 100 000 treatment doses of VIGIV.
Cangene delivered an initial consignment of VIGIV to the
Strategic National Stockpile in March 2004.
In the UK in 2002, the Department of Health issued Guide-
lines for Smallpox Response and Management in the Post-
Eradication Era,30 which include planning for a smallpox
outbreak (e.g., alert levels, regional diagnosis and response
groups, care centers, and vaccination strategy), assessment
and management of initial and subsequent cases (e.g., iso-
lation, management, and tracing of contacts), vaccination
(including mass vaccination, assessment of efficacy, and
awareness of contraindications and complications), use of
VIG, and enhanced surveillance and communication strate-
gies. UK smallpox vaccine stockpiles include first and second
generation vaccines from different suppliers.
Many countries are stockpiling smallpox vaccine (first
and/or second generation vaccines) and the WHO is also
building new stocks to help countries without the resources
to build their own.31 There is currently no common stock-
piling of smallpox vaccine at the level of the European Union
(EU); most member states follow their own national strategy,
with the aim of having at least one vaccine dose per inha-
bitant.32 Next steps at EU level include increase in the
availability of VIG, which is currently in very short supply.32
Complications of smallpox vaccine and
guidelines for management
Range of adverse reactions
Complications of smallpox vaccination range from minor
local and systemic reactions such as local pain, fever, andTable 3 Anticipated adverse events in the US smallpox vaccinat
DoD v
Preventable
Eczema vaccinatum 0
Progressive vaccinia 0
Fetal vaccinia 0
Contact transmission — nosocomial 0
Contact transmission — not nosocomial 50 se
Auto-inoculation — non-ocular 62
Auto-inoculation — ocular 16
Not preventable
Generalized vaccinia (all mild, no sequelae) 35 su
Post-vaccination encephalitis 1
Reprinted with permission from Elsevier, # 2005.headache, which require nomore than symptomatic manage-
ment with non-prescription analgesics, through ‘robust take’
(a powerful response to the vaccine), to serious reactions
such as encephalitis and progressive vaccinia (Table 1).9
Incidence of serious reactions
A review of worldwide reports of serious adverse reactions to
various first-generation smallpox vaccines from 1924 through
the 1960s suggested that encephalitis may be the most
common, but probably strain-dependent, complication, with
reported rates ranging from 2 to 1200 cases per million
vaccinations, although encephalopathy, eczema vaccinatum,
and generalized vaccinia were not infrequent in some reports
(Table 2).6 Reported rates of myopericarditis following vac-
cination with Dryvax1 were generally low in these early
studies.6
In the US smallpox vaccination program that followed
September 11, 2001, the pattern of adverse events was
somewhat different. As of January 2004, the US Department
of Health and Human Services (DHHS) had vaccinated
approximately 40 400 people, and as of January 2005, the
Department of Defense (DoD) had vaccinated 730 580 service
members.6 There were no reported cases of eczema vacci-
natum, progressive vaccinia, or fetal vaccinia, and only two
cases of encephalitis among this total population of around
770 000 subjects (Table 3).6 This reduced rate of adverse
reactions compared to the civilian vaccination program of
the 1950s and 1960s is very likely to be due to effective
screening of potential vaccinees for contraindications. The
rate of ocular complications was also relatively low, probablyion program from 2002 onwards (from Poland et al.)6
accines (n = 730 580) DHHS vaccines (n = 40 422)
0
0
0
0
condary, 2 tertiary 0
20
3
spect, 8 probable 2 suspect, 1 confirmed
1
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Table 4 Unanticipated myopericarditis in the US smallpox vaccination program from 2002 onwards (from Poland et al.)6
DoD vaccines (n = 730 580) DHHS vaccines (n = 40 422)
Myopericarditis 86 (incidence 1:8500) 21 (incidence 1:2000)
Suspected 8 16
Probable 74 5
Confirmed 4 0
Reprinted with permission from Elsevier, # 2005.as a result of both careful screening of vaccinees and training
prior to vaccination to prevent accidental inoculation. Rates
of myopericarditis, however, were relatively high compared
to the earlier reports (Table 4),6 probably because the vac-
cine recipients had not been screened for cardiac risk fac-
tors,21 in view of the apparently low risk in earlier reports.
Myopericarditis is a smallpox vaccine class effect, regardless
of strain or generation,33,34 and it should be noted that most
of the recently reported cases recovered rapidly and com-
pletely.35 Nevertheless, as stated earlier, evidence of heart
disease has now been added to the list of contraindications
for smallpox vaccine in individuals not exposed to variola
virus.
Management of serious complications
The USA has led the way in integrating VIG within prepared-
ness policies. USA guidelines for the medical management of
serious complications of smallpox vaccination are summar-
ized in Table 5.9 Historically, intramuscular (IM) VIG was the
only formulation available. However, this has since been
superseded by intravenous VIG (VIGIV), which is the only
licensed product currently available from the CDC for the
treatment of complications of vaccinia vaccination.9,24
VIGIV (Cangene) and VIGIV (Dynport) were both licensed
by the FDA in 2005 for the management of patients with
progressive vaccinia, eczema vaccinatum, severe general-
ized vaccinia, and extensive body surface involvement or
periocular implantation following inadvertent inoculation. As
described in more detail below, use of VIG has been demon-
strated to be an effective strategy for the management of
these adverse events. For example, one study indicated that
the mortality rate associated with eczema vaccinatum was
reduced from 30—40% to 7% after the introduction of VIG.36
Progressive vaccinia has also been shown to resolve following
administration of VIG in many cases of acquired immunode-
ficiency in adults and in eight of 14 subjects with isolated
immunoglobulin defects.37
Although VIG is licensed for the management of perio-
cular implantation of vaccinia virus, it is specifically contra-
indicated for isolated vaccinia keratitis, because of the risk
of corneal scarring.25 However, if there are comorbid con-
ditions requiring VIG that outweigh this risk, the CDC has
indicated that VIG should not be withheld.25 So far, VIG has
shown no benefit in postvaccinial encephalitis but the
pathogenesis of this adverse reaction is not well under-
stood.37 As there is generally no evidence of active infection
in the brain, it is believed that the encephalitis may result
from an immune-mediated response.37 However, there have
been rare reports of vaccinia virus being isolated from
central nervous system tissue post mortem; therefore, if
it were possible to identify patients with active braininfection, VIG may prove to be of some benefit.37 It is also
theoretically possible that a higher dose of VIG may be
required to allow for product breakdown as it crosses the
blood—brain barrier.
The role of VIG in the management of smallpox vaccine-
inducedmyopericarditis is unclear; however, as it is currently
believed that this adverse reaction is immune-mediated
rather than due to an active viral infection, VIG would
probably be of no benefit.35
VIG prophylaxis in vaccinia vaccine adverse
effects
As mentioned above, smallpox vaccination is contraindi-
cated in some groups of people, including those with
eczema or other skin conditions, immunosuppressed per-
sons, infants under 1 year of age, and pregnant or breast-
feeding women.20,22 There is evidence that prophylactic
VIG may be useful in some of these subjects, as described
below.37 However, in the absence of further evaluation, VIG
is not currently recommended for prophylaxis when persons
with contraindications to smallpox vaccination are inad-
vertently exposed to vaccinia and are otherwise well.25
Following the ACIP meeting of February 2003, the consen-
sus was to ‘offer’ VIG to women inadvertently vaccinated
during pregnancy, or with newly diagnosed pregnancy after
vaccination, but to avoid ‘recommending’ VIG use for this
indication.38
Source and preparation of VIG
VIG was first obtained from the plasma of hyperimmunized US
Army recruits in the 1950s and the IM form was used to treat
complications of smallpox vaccination.39 However, it was
determined more recently that IV formulations would
improve both tolerability and pharmacokinetic profile,40
and better accommodate the large volume administered.
VIGIV (Cangene Corporation, US Civilian Stockpile) is a
sterile solution containing the purified gamma globulin (IgG)
fraction of plasma taken from healthy donors previously
vaccinated with live vaccinia virus vaccine (Dryvax1),
who demonstrate high titers of anti-vaccinia virus anti-
body.41 The IgG fraction is purified by the anion-exchange
column chromatography method. The solution is solvent/
detergent-treated to sterilize it, and is stabilized with 10%
maltose and 0.03% polysorbate 80 (pH 5.0—6.5). VIGIV con-
tains no preservative, unlike IM VIG, which contained 0.01%
thimerosol for this purpose, a potentially teratogenic mer-
cury derivative.42
The VIGIV (Cangene) production process ensures that any
risk of viral contamination is reduced to an absoluteminimum.
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Table 5 Guidelines for medical management of serious complications of smallpox (vaccinia) vaccination (from Thorne et al.)9
Serious complication Medical management
Postvaccinial encephalitis No definitive treatment available
VIG not recommended
Supportive care, anticonvulsants, and
hospitalization in ICU should be considered
Progressive vaccinia (vaccinia
gangrenosa, vaccinia necrosum)
VIG recommended: mortality has been
prevented with prompt and adequate
VIG treatment (consult CDC)
No proven benefit of surgical debridement,
or antiviral therapy
Eczema vaccinatum VIG recommended
Observe for secondary infections and
hemodynamic compromise
Generalized vaccinia VIG recommended in severe cases, especially if
underlying immunodeficiency or recurrent
Inadvertent inoculation
(accidental implantation)
Usually self-limited but more serious in
immunocompromised patients
VIG if extensive body surface involvement or
periocular implantation (because of threat to eyesight)
Vaccinia keratitis Immediate consultation with
experienced ophthalmologist
Topical antivirals in consultation with CDC
VIG contraindicated in isolated keratitis
(risk of corneal scarring),
but should not be withheld in subjects with
comorbidities requiring
VIG where the risk outweighs that of corneal scarring
Other rash (e.g. erythema multiforme,
Stevens—Johnson Syndrome, roseola
vaccinia, toxic erythema, and
postvaccinia urticaria)
Typically resolve spontaneously after 2—4
d but hospitalization
and supportive care recommended for
Stevens—Johnson Syndrome
Treat symptoms
Fetal vaccinia VIG efficacy unknown
Antivirals not recommended
Myopericarditis Rule out acute ischemic event and pericardial effusion
NSAIDs or steroids might be indicated
Acute ischemic events Standard of care for acute ischemic events
Reprinted with permission from the American College of Emergency Physicians, # 2003.Everyplasmadonation is screened for thepresenceofhepatitis
B virus (HBV) surface antigen (HBsAg) and antibodies to human
immunodeficiency viruses (HIV-1/2) andhepatitis C virus (HCV)
using FDA-licensed serologic tests.41 The plasma is also tested
by FDA-licensed nucleic acid testing (NAT) for HIV-1 and HCV.
Although still an investigational tool, NAT for HBV is also
performed on all source plasma used.41
The potency of VIGIV (Cangene) is determined by a plaque
reduction neutralization test and expressed as arbitrary units
by comparison to the FDA reference standard. Each vial
contains approximately 40—70 mg/mL total protein and
>50 000 units of vaccinia antibody neutralizing activity.
Although VIGIV predominantly contains IgG, it has also been
shown to contain a very small amount of immunoglobulin A
(IgA) (40 mg/mL).41Efficacy and safety of VIG
Management of smallpox vaccine complications
The clinical efficacy of IM VIG has recently been reviewed by
Hopkins and Lane based on reports in the literature.37 The
authors identified 16 articles that reported the use of IM VIG
for the treatment of smallpox vaccine complications,
although these did not include any formal controlled trials.
Indications for treatment with IM VIG included generalized
vaccinia, progressive vaccinia, eczema vaccinatum, and
some accidental inoculations.
These uncontrolled studies generally reported reductions
in morbidity and mortality with VIG compared to observed
rates in untreated patients.37 There were no fatalities among
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Table 6 Prevention of smallpox with VIG among exposed
individuals (from Hopkins and Lane)37
Study (year) No. of close contacts with smallpox
after exposure/no. of close contacts
with exposure (%)
Vaccination + VIG Vaccination alone
Kempe (1960) 2/56 (3.8) 8/75 (10)
Kempe (1961) 5/326 (1.5) 21/379 (5.5)
Hobday (1962) 2/56 (3.6) 8/75 (10.6)
Marennikova (1962) 0/13 (0) 13/29 (45)
Reprinted with permission from the University of Chicago,# 2004
by the Infectious Diseases Society of America. All rights reserved.over 800 VIG-treated subjects with generalized vaccinia and
over 600 with accidental infection. Mortality was around 10%
or less in cases of eczema vaccinatum treated with VIG, and
around 25% in vaccinia encephalitis, although patient num-
bers were small in the latter case (ranging from 2 to 45 in
various studies). There were also few reported cases of
patients with progressive vaccinia treated with VIG (range
1 to 24 in different studies), with mortality ranging from 0/9
patients to 7/7 patients. Generally, there was a suggestion
that mortality was reduced in these patients.
Prophylaxis of smallpox vaccine complications
Six publications reported the efficacy of IM VIG for the
prophylaxis of vaccinial superinfection of eczema, burns,
chickenpox, immunosuppression, pregnancy, or certain skin
conditions, although these were not placebo-controlled stu-
dies.37 The results showed that two of 810 eczema patients
and none of 126 subjects with other skin conditions devel-
oped vaccine complications when pre-treated with VIG. Only
one of 205 immunocompromised patients, three of 64 preg-
nant women and none of 18 with burns or chickenpox devel-
oped complications when VIG was used as prophylaxis prior to
vaccination.
There has been one large controlled study in which
healthy Dutch military recruits were given VIG or placebo
together with smallpox vaccination with the aim of deter-
mining rates of vaccinia encephalitis.37,43 The results showed
only three cases of encephalitis among 53 630 individuals
given VIG prophylaxis, compared to 13 cases of encephalitis
among 53 044 recruits given placebo, and there were very
few complications associated with VIG. While far from con-
clusive, these findings suggest that VIG had a prophylactic
effect in these subjects.
Prevention of smallpox in exposed individuals
Four controlled studies and one observational study have
reported the use of IM VIG to prevent smallpox in contacts of
patients with documented cases of smallpox, with (in the
words of Hopkins and Lane) ‘‘varying but promising results’’
(Table 6).37
Pharmacokinetics and safety of IM VIG and VIGIV
IM VIG appeared to be generally safe, although a few
instances of allergic or anaphylactoid systemic reactions
were reported, and occasional local tenderness and stiffnessTable 7 Clinical pharmacology of VIGIV: test of non-inferiority v
Dose VIGIV, U/kg Plasma levelsa U/mL (CI)
VIGIVc IM VIG d
6000 60.1 (36.1—84.6) 66.2 (42
9000 90.3 (63.4—133.8) 64.8 (47
CI: confidence interval.
a Geometric mean (range).
b Expressed as a percentage relative to the geometric mean of the sim
c Observed levels.
d Simulated levels.occurred, persisting from a few hours to 1—2 days following
injection.25,42 The IM VIG package insert recommended that
ephedrine or other suitable medication be available for
treating anaphylactoid reactions.42
VIGIV is a new product and therefore its efficacy has not yet
been tested in clinical situations. There are, however, phar-
macokinetic and safety data from studies in healthy volun-
teers. Hopkins et al. have recently reported on the safety and
pharmacokinetics of two experimental IV formulations of VIG
developedby theUSmilitary (one lyophilizedandone liquid) in
healthy volunteers.40 The results showed that VIGIV at the
target dose achieved plasma levels that were not inferior to
predicted levels after IM VIG injection. Treatment-related
adverseevents typical of hyperimmune therapywere reported
in 5—7% of subjects, including headache, injection-site reac-
tion, and nausea, and there were no serious adverse events.
The authors concluded that their studies suggest that IV
administration of VIG is well tolerated and results in a more
favorable pharmacokinetic profile than IM VIG.
The clinical pharmacology and pharmacodynamics of
VIGIV (Cangene) have been assessed in two phase 1, rando-
mized, double-blind studies.41 The clinical pharmacology of
VIGIV was assessed in 60 healthy volunteers randomized to
receive either 6000 units/kg or 9000 units/kg VIGIV. A five-
day time point was selected for assessment of results, as this
is the approximate time of peak serum antibody levels
following IM administration of other human immune globulin
products. The results showed that the binding capacity and
neutralizing antibody activity of anti-vaccinia antibody five
days after VIGIV administration (at both dosages) were at
least as high as the theoretical values that would be achieved
with IM VIG (Table 7). It should be noted that no historical
pharmacokinetic data are available for IM VIG.ersus IM VIG41
Ratio of means % (97.5 lower CI bound) b
.3—94.9) 90.82 (86.95)
.6—87.2) 139.40 (135.27)
ulated concentrations at day 5 after 6000 U/kg IM administration.
200 R. WittekNo serious adverse events were reported during the VIGIV
(Cangene) clinical pharmacology study. Of the events
reported, 85% were mild and 15% were moderate in severity.
Headache was the most frequent adverse event, followed by
rigors, dizziness and nausea. All adverse events that were
considered related to VIGIV were typical of those expected
following IV administration of protein.44
The pharmacodynamics of VIGIV (Cangene) were assessed
in 32 healthy volunteers who were randomized to receive
vaccinia vaccination with or without VIGIV.41 The objectives
were to assess the effects of VIGIVon local and immunological
responses to vaccinia vaccination and to characterize further
the safety of VIGIV. The results showed that concurrent
administration of VIGIV and vaccinia vaccine does not alter
the safety profile of VIGIV compared to the findings of the
pharmacokinetic study.
The other FDA-licensed IV formulation of VIG (Dynport)
has been tested clinically in healthy volunteers and was
reported to be well tolerated.45
General comments on VIG safety
Serious adverse events with VIGIV are anticipated to be
similar to those observed with other IV immune globulin
products, and may include hypotension, anaphylaxis and
anaphylactoid systemic reactions, renal dysfunction, and
aseptic meningitis syndrome.25 Persons administering VIGIV
should be aware that persons with selective IgA deficiency
might have anaphylactic reactions to blood products that
contain IgA.25 It is not known whether VIG causes fetal harm
when administered during pregnancy, nor whether it is
excreted in breastmilk; therefore, VIG should only be offered
to pregnant women if clearly needed, and caution should be
exercised in breastfeeding women.25 It may be noted that
WinRho (Rh0 (D) Immune Globulin (Human)), a passive immu-
nizing agent used for the prevention of Rh immunization and
treatment of idiopathic thrombocytopenic purpura, is pro-
duced by the same process as VIGIV (Cangene) and has been
safely administered to pregnant women and infants.46
While still in use, IM VIG was specifically contraindicated
by the FDA for use in pregnancy because of potentially
teratogenic levels of mercury,47 a risk that does not exist
with VIGIV.
VIG products are solvent/detergent-treated and undergo
size-exclusion based filtration steps to reduce the risk of
contamination with viruses and other infectious agents.
While a theoretical risk remains, donor screening and recent
manufacturing processes have reduced this risk.25
Dosing and administration of VIGIV (Cangene)
The recommended dosage of VIGIV (Cangene) for the man-
agement of severe complications of smallpox (vaccinia) vac-
cination (indications listed above) is 6000 U/kg, to be given
as soon as symptoms appear.41 Repeat dosing may be con-
sidered if symptoms persist or are severe, although there are
currently no clinical data on repeat doses. VIGIV should be
given through a dedicated IV line at a maximum rate of 2 mL/
min (max 0.04 mL/kg/min in individuals weighing<50 kg). In
pediatric or geriatric patients, it is suggested that the pro-
duct be infused more slowly in the event of a minor adversereaction (e.g., flushing), or in the presence of risk factors for
thrombosis/thromboembolism and/or renal insufficiency. All
partially used vials of VIGIV should be discarded.
Conclusions
The reintroduction of smallpox vaccination in response to the
risk of bioterrorism has brought with it a need to manage the
adverse complications of smallpox vaccine, and considera-
tion of alternative prophylaxis in persons for whom vaccina-
tion is contraindicated. VIG represents an important
component of preparedness policies and is currently indi-
cated for the management of a number of serious adverse
reactions to smallpox (vaccinia) vaccination. Stockpiling of
VIG is underway in the USA and on the agenda in the EU.
Intravenous formulations of VIG are currently being manu-
factured and offer clinical advantages over IM VIG, including
rapid distribution, lack of mercury derivatives, and ease of
administration. Studies are needed to evaluate further the
usefulness of VIG for prophylactic use in at-risk individuals
and in post-exposure settings or treatment of smallpox in the
clinical setting.
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